metformin has been researched along with Response Evaluation Criteria in Solid Tumors in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers." | 2.82 | Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. ( Fu, S; Hong, D; Janku, F; Karp, D; Khawaja, MR; Lu, KH; Madhusudanannair, V; McQuinn, LM; Meric-Bernstam, F; Naing, A; Ng, CS; Nick, AM; Piha-Paul, SA; Subbiah, V; Tsimberidou, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| El Shorbagy, S | 1 |
| abuTaleb, F | 1 |
| Labib, HA | 1 |
| Ebian, H | 1 |
| Harb, OA | 1 |
| Mohammed, MS | 1 |
| Rashied, HA | 1 |
| Elbana, KA | 1 |
| Haggag, R | 1 |
| Khawaja, MR | 1 |
| Nick, AM | 1 |
| Madhusudanannair, V | 1 |
| Fu, S | 1 |
| Hong, D | 1 |
| McQuinn, LM | 1 |
| Ng, CS | 1 |
| Piha-Paul, SA | 1 |
| Janku, F | 1 |
| Subbiah, V | 1 |
| Tsimberidou, A | 1 |
| Karp, D | 1 |
| Meric-Bernstam, F | 1 |
| Lu, KH | 1 |
| Naing, A | 1 |
2 trials available for metformin and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2021 |
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Res | 2016 |